Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer.
Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer.
复制标题
DOI：
10.1038/s41391-022-00598-3
复制
发表时间：
2023-03
影响因子：
4.8
通讯作者：
Armstrong, Andrew J.
中科院分区：
文献类型：
--
作者：
Wang, Edina C.;Lee, W. Robert;Armstrong, Andrew J.
Evolving data suggests that men with high-risk localized prostate cancer may benefit from more potent androgen receptor inhibition in the context of curative intent radiotherapy. Recently updated American Society for Clinical Oncology (ASCO) evidence-based guidelines and the National Comprehensive Cancer Network (NCCN) Guidelines have updated recommendations for the consideration of adding second generation anti-androgens to androgen deprivation therapy (ADT) in men receiving radiation therapy (RT) for noncastrate locally advanced high and very high risk nonmetastatic or node positive prostate cancer. We conducted a comprehensive review of existing published and abstract presented evidence behind RT with ADT for the definitive management of high-risk prostate cancer, particularly focused on the current phase II and III trial evidence for the addition of second generation anti-androgens to ADT in definitive RT treatment of high-risk prostate cancer and specifically focused on the recent STAMPEDE trial results with abiraterone acetate. We review the biological mechanisms in which second generation anti-androgens may help mitigate ADT resistance and provide radiosensitization through inhibition of DNA repair. Finally, we discuss ongoing clinical trials of potent AR inhibitors with ADT in this non-metastatic high-risk radiotherapy setting that may inform on future treatment guidelines. Recent data suggest an overall survival benefit as well as increased probabilities of disease free and metastasis free survival in men with high and very high risk localized, node positive, and oligometastatic hormone sensitive prostate cancer with abiraterone acetate and prednisone and support the use of potent AR inhibitors in this setting after informed decision making.
登录
查看更多内容
影响因子：
82.9
作者：
Beltran H;Prandi D;Mosquera JM;Benelli M;Puca L;Cyrta J;Marotz C;Giannopoulou E;Chakravarthi BV;Varambally S;Tomlins SA;Nanus DM;Tagawa ST;Van Allen EM;Elemento O;Sboner A;Garraway LA;Rubin MA;Demichelis F
通讯作者：
Demichelis F
影响因子：
64.5
作者：
Cancer Genome Atlas Research Network
通讯作者：
Cancer Genome Atlas Research Network
DOI：
10.1016/s0140-6736(21)02437-5
发表时间：
2022-01-29
期刊：
Lancet (London, England)
影响因子：
--
作者：
Attard G;Murphy L;Clarke NW;Cross W;Jones RJ;Parker CC;Gillessen S;Cook A;Brawley C;Amos CL;Atako N;Pugh C;Buckner M;Chowdhury S;Malik Z;Russell JM;Gilson C;Rush H;Bowen J;Lydon A;Pedley I;O'Sullivan JM;Birtle A;Gale J;Srihari N;Thomas C;Tanguay J;Wagstaff J;Das P;Gray E;Alzoueb M;Parikh O;Robinson A;Syndikus I;Wylie J;Zarkar A;Thalmann G;de Bono JS;Dearnaley DP;Mason MD;Gilbert D;Langley RE;Millman R;Matheson D;Sydes MR;Brown LC;Parmar MKB;James ND;Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators
通讯作者：
Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators
DOI：
10.1016/s0140-6736(15)01037-5
发表时间：
2016-03-19
期刊：
Lancet (London, England)
影响因子：
--
作者：
James ND;Sydes MR;Clarke NW;Mason MD;Dearnaley DP;Spears MR;Ritchie AW;Parker CC;Russell JM;Attard G;de Bono J;Cross W;Jones RJ;Thalmann G;Amos C;Matheson D;Millman R;Alzouebi M;Beesley S;Birtle AJ;Brock S;Cathomas R;Chakraborti P;Chowdhury S;Cook A;Elliott T;Gale J;Gibbs S;Graham JD;Hetherington J;Hughes R;Laing R;McKinna F;McLaren DB;O'Sullivan JM;Parikh O;Peedell C;Protheroe A;Robinson AJ;Srihari N;Srinivasan R;Staffurth J;Sundar S;Tolan S;Tsang D;Wagstaff J;Parmar MK;STAMPEDE investigators
通讯作者：
STAMPEDE investigators
DOI：
10.1056/nejmoa1702900
发表时间：
2017-07-27
期刊：
The New England journal of medicine
影响因子：
--
作者：
James ND;de Bono JS;Spears MR;Clarke NW;Mason MD;Dearnaley DP;Ritchie AWS;Amos CL;Gilson C;Jones RJ;Matheson D;Millman R;Attard G;Chowdhury S;Cross WR;Gillessen S;Parker CC;Russell JM;Berthold DR;Brawley C;Adab F;Aung S;Birtle AJ;Bowen J;Brock S;Chakraborti P;Ferguson C;Gale J;Gray E;Hingorani M;Hoskin PJ;Lester JF;Malik ZI;McKinna F;McPhail N;Money-Kyrle J;O'Sullivan J;Parikh O;Protheroe A;Robinson A;Srihari NN;Thomas C;Wagstaff J;Wylie J;Zarkar A;Parmar MKB;Sydes MR;STAMPEDE Investigators
通讯作者：
STAMPEDE Investigators